Currently out of the existing stock ratings of Francois Brisebois, 188 are a BUY (95.92%), 1 are a SELL (0.51%), 7 are a HOLD (3.57%).

Francois Brisebois

Work Performance Price Targets & Ratings Chart

Analyst Francois Brisebois, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 45.49% that have a potential upside of 55.23% achieved within 284 days.

Francois Brisebois’s has documented 371 price targets and ratings displayed on 40 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TARS, Tarsus Pharmaceuticals at 12-Aug-2026.

Wall Street Analyst Francois Brisebois

Analyst best performing recommendations are on DMTK (DERMTECH).
The best stock recommendation documented was for KALA (KALA PHARMACEUTICALS) at 4/14/2025. The price target of $15 was fulfilled within 142 days with a profit of $11.51 (329.8%) receiving and performance score of 23.23.

Average potential price target upside

of $1776.88 (84.37%) on PCSA (PROCESSA PHARMACEUTICALS).
of $83.36 (141.41%) on PRAX (PRAXIS PRECISION MEDICINES ).
of $42.92 (77.01%) on CYBN (CYBIN ).

AVDL Avadel Pharmaceuticals PLC DRRX Durect FLXN Flexion Therapeutics HRMY Harmony Biosciences Holdings ICAD icad inc KALA Kala Pharmaceuticals ACHV Achieve Life Sciences AQST Aquestive Therapeutics CMPS Compass Pathways Plc DMTK DermTech ICPT Intercept Pharmaceuticals OTIC Otonomy CYBN Cybin DMAC DiaMedica Therapeutics PCSA Processa Pharmaceuticals TARS Tarsus Pharmaceuticals SLP Simulations Plus MDWD Mediwound Ltd MNMD Mind Medicine BNGO Bionano Genomics DYN Dyne Therapeutics MDXH MDxHealth SA ADR SERA Sera Prognostics SVRA Savara CNTA Centessa Pharmaceuticals PLC ADR PRAX Praxis Precision Medicines TRDA Entrada Therapeutics AERI Aerie Pharmaceuticals BSGM BioSig Technologies, Common Stock CLSD Clearside Biomedical EBS Emergent Biosolutions GEMP Gemphire Therapeutics GLMD Galmed Pharmaceuticals Ltd NRBO Neurobo Pharmaceuticals SNSE Sensei Biotherapeutics ADVM Adverum Biotechnologies OVID Ovid Therapeutics ABEO Abeona Therapeutics AVD American Vanguard SBBP Strongbridge Biopharma plc

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Benjamin Burnett (WELLS FARGO)